Biotech · Private company
Okyo Pharma Ltd
Track this companyFree. Adds Okyo Pharma Ltd to your Dealase workspace and tells you when its record changes.
Clinical trials31 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- Urcosimod ophthalmic solution is a preservative-free topical ophthalmic product; supplied in unit dose ampoules; administered QID for 12-weeks.Phase 3 · Neuropathic Corneal PainClinicalTrials.gov · fetched Nov 12, 2026
- Vehicle Ophthalmic SolutionPhase 3 · Neuropathic Corneal PainClinicalTrials.gov · fetched Nov 12, 2026
- OK-101Phase 2 · Dry Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- OK-101 0.05%Phase 2 · Neuropathic PainClinicalTrials.gov · fetched Nov 12, 2026
- OK-101 0.1%Phase 2 · Neuropathic PainClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study Assessing the Safety and Efficacy of Urcosimod Ophthalmic Solution in Participants With Neuropathic Corneal Pain (NCP).PHASE3 · NOT_YET_RECRUITING · started Sep 1, 2026ClinicalTrials.gov NCT07838506 · fetched Nov 12, 2026
- The Study Assessing the Safety and Efficacy of OK-101 Treatment in Subjects With Neuropathic Corneal PainPHASE2 · TERMINATED · started Oct 15, 2024ClinicalTrials.gov NCT06637527 · fetched Nov 12, 2026
- The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye DiseasePHASE2 · COMPLETED · started Apr 28, 2023ClinicalTrials.gov NCT05759208 · fetched Nov 12, 2026